Member Info for checkricky

I'M sticking the facts and the last few RNS'S and especially the one today hopefully now that the BID & ASK has started to move up now. We will begin to move higher as we get into the afternoon

The net proceeds of this subscription will be dedicated to the imminent commencement of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HEMO-CAR-T" or "HG-CT-1"), aimed at treating acute myeloid leukemia ("AML").

The Company will keep the Market informed of future developments as trials commence and develop.

This getting ready to take off big time the long awaited trials are about to commence just awaiting the big go-ahead now..

Well with over £250,000 of shares bought today you would think things are warming up yum yum 😋

And we all know when Hemogenyx moves up 50% upside is no big deal.. The upside from current level is massive

Strong 💪 £15,000 BUYS SOMEONE'S CONFIDENT

OVER £210,000 BOUGHT NOW..

OVER £200,000 BUYS TODAY OUTSTRIPPING ANY SELLING

ANYONE SELLING IS GETTING BOUGHT OUT

BIG RNS TO TAKE HEMOGENYX TO ANOTHER LEVEL TO LAND VERY SOON..

Someone is buying bigtime £15,000 buys going through every few minutes now on L2 now... 💰💰💰

Big chunky buying going on L2 now as we go into the afternoon..

Onwards and upwards from here good strong 💪 buying today that's for sure..

Hemo secures funding for clinical trials well done Hemogenyx 👏 👏👏👏

The net proceeds of this subscription will be dedicated to the imminent commencement of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HEMO-CAR-T" or "HG-CT-1"), aimed at treating acute myeloid leukemia ("AML").

The Company will keep the Market informed of future developments as trials commence and develop.

This getting ready to take off big time the long awaited trials are about to commence just awaiting the big go-ahead now..

It's all coming together now a lot of buying going on today as we enter a very busy week for Hemogenyx..

It's all about being in or out now and I'm all in and ready for the trials... Very Very simple I do not want to miss out on this amazing opportunity.....

We are now on 11th day of Nov and hopefully picking up some momentum for the ultimate mother of all RNS'S to land by the end of this week or next week which will defo be the 3rd week into Nov indicating the first real concrete confirmation on the start date for the phase 1 of clinical trials...

Brum Brum I can't wait for Hemogenyx to get this show on the road 💰💰💰

I see doomsdayers like Tuan6 are on bb & on the Hemo bb looking for investors to sell up so they can pickup your shares on the cheap.. Please don't be fooled by him his been doing the same on the Hemo bb getting investors to sell up so he can buy in cheaper...

This share has been hit hard by the court decision however it will recover in good time. You would think what's next would Greg's need to declare who and what they pay to the company who supplies the sausages for the rolls next.. ffs the world is going mad and the ambulance chasers are ready to process your claims for a whopping fee...

Stay focused lady's & Gents this is a very interesting & important time for Hemogenyx Pharmaceuticals don't be distracted by the nonsense & noise as stated earlier

Take a minute and absorb what the last few RNS'S are telling us shareholders, and understand the huge once in a life time opportunitie Hemogenyx is presenting to us shareholders, the shareprice is amazingly cheap due to the constant trading by some greedy Investors and the same handful of shorters that clogged up social media and bb like this one just to spook long-term holders into selling... However the time has finally arrived for the official launch of the Phase I clinical trial and things are about to change for the better and I'm expecting the shareprice to gradually move higher day by day as we near the official launch date....

Snippets taken from the last RNS

Hemogenyx has successfully completed the necessary contracts and budgeting preparations to advance HG-CT-1 into clinical testing. Institutional Review Board (IRB) approval at the initial clinical site is anticipated by "the second week of November". Following IRB clearance, a Site Initiation Visit (SIV) is expected to take place in the "third week of November", marking the official launch of the Phase I clinical trial.

This Phase I trial is designed as a dose-escalation study to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. Key secondary objectives include assessing the therapy's impact on the following clinical outcomes:

· Efficacy of HG-CT-1 based on AML-specific response criteria

· Overall survival (OS) rates among participating subjects

· Progression-free survival (PFS) in evaluable subjects

· Duration of response (DoR) in those who achieve clinical responses

These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options. The commencement of this trial will represent a major milestone for Hemogenyx Pharmaceuticals, enabling the Company to advance this promising therapy into clinical testing at one of the world's most prestigious cancer research institutions.

Lovely Jubely 👌 👍

We are now finally at this long long awaited important stage of Hemogenyx honestly if I was a shareholder I would hold on to all my shares now and not sell any at this ridiculously low levels if fact I would as and when possible add more..

And if I was shorting this stock due to an anticipated placing a few weeks ago that is no longer needed I would be seriously be thinking of closing my position as soon as I can before the next RNS lands.. It will be squeaky bum time very very soon for anyone shorting hemogenyx now..

Take a minute and absorb what the last few RNS'S are telling us shareholders, and understand the huge once in a life time opportunitie Hemogenyx is presenting to us shareholders, the shareprice is amazingly cheap due to the constant trading by some greedy Investors and the same handful of shorters that clogged up social media and bb like this one just to spook long-term holders into selling... However the time has finally arrived for the official launch of the Phase I clinical trial and things are about to change for the better and I'm expecting the shareprice to gradually move higher day by day as we near the official launch date....

Snippets taken from the last RNS

Hemogenyx has successfully completed the necessary contracts and budgeting preparations to advance HG-CT-1 into clinical testing. Institutional Review Board (IRB) approval at the initial clinical site is anticipated by "the second week of November". Following IRB clearance, a Site Initiation Visit (SIV) is expected to take place in the "third week of November", marking the official launch of the Phase I clinical trial.

This Phase I trial is designed as a dose-escalation study to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. Key secondary objectives include assessing the therapy's impact on the following clinical outcomes:

· Efficacy of HG-CT-1 based on AML-specific response criteria

· Overall survival (OS) rates among participating subjects

· Progression-free survival (PFS) in evaluable subjects

· Duration of response (DoR) in those who achieve clinical responses

These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options. The commencement of this trial will represent a major milestone for Hemogenyx Pharmaceuticals, enabling the Company to advance this promising therapy into clinical testing at one of the world's most prestigious cancer research institutions.

Lovely Jubely 👌 👍

Getting ready to lift off very very soon now baby 💪🍾

I'm holding on 4 Gold now ✨️

Last 10 or so RNS'S tell you exactly what you need to know especially the last few...

Schedule for Phase I Clinical Trial Opening

Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1)

Hemogenyx Pharmaceuticals plc (LSE: HEMO), a biopharmaceutical company focused on developing breakthrough therapies for blood diseases, is pleased to announce the schedule for the opening of the first clinical site for its lead asset, HEMO-CAR-T, formally designated HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults.

The Company has successfully completed the necessary contracts and budgeting preparations to advance HG-CT-1 into clinical testing. Institutional Review Board (IRB) approval at the initial clinical site is anticipated by the second week of November. Following IRB clearance, a Site Initiation Visit (SIV) is expected to take place in the third week of November, marking the official launch of the Phase I clinical trial.

This Phase I trial is designed as a dose-escalation study to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. Key secondary objectives include assessing the therapy's impact on the following clinical outcomes:

· Efficacy of HG-CT-1 based on AML-specific response criteria

· Overall survival (OS) rates among participating subjects

· Progression-free survival (PFS) in evaluable subjects

· Duration of response (DoR) in those who achieve clinical responses

These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options. The commencement of this trial will represent a major milestone for Hemogenyx Pharmaceuticals, enabling the Company to advance this promising therapy into clinical testing at one of the world's most prestigious cancer research institutions.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Launching this Phase I clinical trial for HG-CT-1 will mark a critical step forward in our mission to develop transformative therapies for patients battling relapsed and refractory acute myeloid leukemia. For patients who have few remaining treatment options, HG-CT-1 offers a potentially life-saving solution. We are eager to initiate this trial and generate data that will be essential in advancing this therapy toward broader clinical use. This milestone underscores our commitment to innovation and our dedication to addressing the urgent needs of patients with severe blood cancers."

Good Good Morning to everyone, well it now officially November 2024 and as it stands we are about to start the long long awaited phase 1 of the clinical trials in ONLY a few weeks now. Hemogenyx's science is actually absolutely amazing and it will be truly amazing when the day arrives and this company goes onto saving lives.

Hemogenyx is now getting ready to advance forward into clinical trials

A BIG historical positive change and yet the same old rubbish from the same old hand full of penny pinching mugs..

Well it's getting very obvious now hemogenyx is the share to be holding onto...

Brilliant RNS Hemogenyx 👏

A few doomsdayers out penny pinching shopping for a cheap cheeky bargain I see. And I don't blame yah

This motor finance thing has been brewing in the background for over a year now and we all know that..

As we all know CB will be appealing the decision. Lloyds has set aside funds for this matter to be addressed and if needed can also put further funds aside for this to be addressed....

Lloyds is making mega bucks now and has a good dividend payout. And as far as I can remember the banks always get robbed by the political leaders that's how it is and that's how it will always be.

The shareprice will soon bounce back up as the market move onto something else.....

Stay strong lads and lady's this will soon be above 63p very soon.....

A very good possibility